Stryker Corporation
SYK
Classifica tra le azioni
#191
Stryker Corporation functions as a prominent medical technology enterprise,... Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Prezzo delle azioni
$304.72
Capitalizzazione di mercato
$116.88B
Variazione (1 giorno)
1.96%
Variazione (1 anno)
-20.07%
Paese
US
Scambia Stryker Corporation (SYK)
Categoria
Healthcare
Rapporto P/E per Stryker Corporation (SYK)
Rapporto P/E al October 2026 TTM: 28.94
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Stryker Corporation, il rapporto P/E attuale (TTM) è 28.94. Alla fine del 2024, il rapporto P/E era 45.83.
Storico del rapporto P/E per Stryker Corporation da 2000 a 2026
Rapporto P/E alla fine di ogni anno
| Anno | Rapporto P/E | Cambia |
|---|---|---|
| 2026 (TTM) | 28.94 | -30.05% |
| 2025 | 41.38 | -9.71% |
| 2024 | 45.83 | 27.61% |
| 2023 | 35.92 | -8.41% |
| 2022 | 39.21 | -22.44% |
| 2021 | 50.56 | -12.14% |
| 2020 | 57.54 | 52.66% |
| 2019 | 37.69 | 128.39% |
| 2018 | 16.50 | -70.93% |
| 2017 | 56.77 | 108.63% |
| 2016 | 27.21 | 11.88% |
| 2015 | 24.32 | -64.92% |
| 2014 | 69.33 | 145.16% |
| 2013 | 28.28 | 75.92% |
| 2012 | 16.07 | 12.53% |
| 2011 | 14.28 | -14.55% |
| 2010 | 16.72 | -7.52% |
| 2009 | 18.08 | 27.26% |
| 2008 | 14.20 | -52.79% |
| 2007 | 30.09 | 4.28% |
| 2006 | 28.85 | 8.62% |
| 2005 | 26.56 | -36.09% |
| 2004 | 41.57 | 6.61% |
| 2003 | 38.99 | -3.57% |
| 2002 | 40.43 | -4.42% |
| 2001 | 42.30 | -5.53% |
| 2000 | 44.78 | 0.00% |
Rapporto P/E per aziende simili o concorrenti
| Azienda | P/E Ratio | Differenza del P/E Ratio | Il paese |
|---|---|---|---|
| 33.11 | 14.39% |
US
|
|
| 21.39 | -26.11% |
IE
|
|
| 17.34 | -40.10% |
US
|
|
| - | - |
DE
|
|
| 49.68 | 71.65% |
US
|
Come leggere un P/E ratio?
Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.
Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.
Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.